Bladder Cancer

Papers
(The median citation count of Bladder Cancer is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
FGFR3 – a Central Player in Bladder Cancer Pathogenesis?10
Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol8
Impact of Intestinal Urinary Diversion on the Risk of Fracture and Loss of Bone Mass: A Systematic Review6
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors6
Optimizing Nutritional Status in Patients Undergoing Radical Cystectomy: A Systematic Scoping Review6
Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate5
Quality of Life and Health State Utilities in Bladder Cancer5
Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen5
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models5
The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy4
Synthesis, Characterization, and Biological Activity of Anthraquinone-Substituted Imidazolium Salts for the Treatment of Bladder Cancer4
“Picture this”- Patients’ Drawings of Non-Muscle Invasive Bladder Cancer: A Novel Method to Help Understand How Patients Perceive Their Condition4
Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer4
Early Bone Metastases are Associated with Worse Outcomes in Metastatic Urothelial Carcinoma4
The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands4
A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer4
Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed3
Quality of Life and Anxiety in Patients with First Diagnosed Non-Muscle Invasive Bladder Cancer Who Receive Adjuvant Bladder Therapy3
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer3
Qualitative Analysis of Pain in Patients With Locally Advanced or Metastatic Urothelial Carcinoma3
Accuracy of Inchworm Sign on Diffusion-Weighted MRI in Differentiating Muscle-Invasive Bladder Cancer3
Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model3
Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment3
What is a Bladder Cancer Molecular Subtype?3
Identification of Sex Differences in Tumor-Specific T Cell Infiltration in Bladder Tumor-Bearing Mice Treated with BCG Immunotherapy3
CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract3
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Re3
Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer3
Comorbidity Scores and Machine Learning Methods Can Improve Risk Assessment in Radical Cystectomy for Bladder Cancer2
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the World Health Organization Classification of the Urinary and Male Genital Tumors2
Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials2
Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma2
Significance and Mechanisms Analyses of RB1 Mutation in Bladder Cancer Disease Progression and Drug Selection by Bioinformatics Analysis2
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E2
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter2
Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab2
MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease2
Hyperthermia Improves Solubility of Intravesical Chemotherapeutic Agents2
5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence2
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile2
Safety and Pharmacokinetics of Intravesical Chitosan/Interleukin-12 Immunotherapy in Murine Bladders2
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors2
A Procedural Checklist for Transurethral Resection of Bladder Tumors (TURBT) Enhances Operative Dictation and Assesses Surgeon Accuracy of Tumor Characteristic Predictions2
Lung Metastases Versus Second Primary Lung Cancers in Patients with Primary Urothelial Carcinoma of the Bladder: A National Population-Based Assessment2
Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations1
Deciding When to Omit Repeat Transurethral Resection of Superficial Bladder Cancer: Do Photodynamic Diagnostics help?1
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer11
The Effect of Metformin on Bladder Cancer Incidence and Outcomes: A Systematic Review and Meta-Analysis1
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward1
Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration1
Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma1
Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark1
Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study1
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States1
Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study1
SH3BP5-AS1/IGF2BP2/VDAC2 Axis Promotes the Apoptosis and Ferroptosis of Bladder Cancer Cells1
Sensitivity and Specificity in Urine Bladder Cancer Markers – Is it that Simple?1
Implementing a New Standard of Care1
Bladder Cancer Health Literacy: Assessing Readability of Online Patient Education Materials1
Identification of a Novel Ferroptosis-Related Gene Signature for Prediction of Prognosis in Bladder Urothelial Carcinoma1
A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma1
Efficacy of EGFR Inhibitors and NSAIDs Against Basal Bladder Cancers in a Rat Model: Daily vs. Weekly Dosing, Combining EGFR Inhibitors with Naproxen, and Effects on RNA Expression1
Urethral Melanoma – Clinical, Pathological and Molecular Characteristics1
LncRNA HEIH/miR-4500/IGF2BP1/c-Myc Feedback Loop Accelerates Bladder Cancer Cell Growth and Stemness1
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer1
Well-being and Perceptions of Supportive Resources among Caregivers of Patients with Bladder Cancer1
Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays0
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?0
Effect of Bacille Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer After Prostate Radiotherapy0
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer0
Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility0
Clinical Trials Corner Issue 10(1)0
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer0
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis0
Challenging Cases in Urothelial Cancer: Case 260
BCG versus Cystectomy for High Risk, High Grade Non Muscle Invasive Bladder Cancer0
Open vs Robotic Surgery0
Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study0
Challenging Cases in Urothelial Cancer: Case 210
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer0
Salvage for BCG Unresponsive and Recurrent Disease0
Challenging Cases in Urothelial Cancer: Case 230
Challenging Cases in Urothelial Cancer: Case 240
The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study10
A New Functional Gene, Zinc Finger Protein 485 (ZNF485), is Involved in Bladder Cancer Proliferation0
Clinical Trials Corner Issue 7(3)0
Challenging Cases in Urothelial Cancer: Case 200
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer0
Clinical Trials Corner Issue 10(2)0
Challenging Cases in Urothelial Cancer: Case 180
The Impact of Dose Reduction of Bacillus Calmette–Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis0
Quality of Life following Chemoradiotherapy for Localized Muscle Invasive Bladder Carcinoma: A Systematic Review0
Low Risk of Severe Complications After a Single, Post-Operative Instillation of Intravesical Chemotherapy in Patients with TaG1G2 Urothelial Bladder Carcinoma0
Clinical Trials Corner Issue 7(2)0
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review0
Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly –An International Multicenter Study0
The Pros and Cons of “Machination of Medicine” in Genitourinary Oncology Practice0
Comparison of Robotic vs Open Cystectomy: A Systematic Review0
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review0
Challenging Cases in Urothelial Cancer0
Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer0
Association of Histone H3 Trimethylation in Circulating Monocytes with Lack of Early Recurrence in Patients with Bladder Cancer following BCG Induction Therapy0
Clinical Trials Corner Issue 9(2)0
Clinical Trials Corner Issue 8(1)0
Challenging Cases in Urothelial Cancer: Case 290
Y Chromosome Loss and Bladder Cancer0
The Development of a Video-based Nutrition Education Curriculum for Patients Undergoing Radical Cystectomy0
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG0
Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life0
Urologists and Advanced Practice Providers Evaluating Hematuria0
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study0
Combination of Two T1 Substaging Systems (T1a/b/c and T1m/e) Better Predicts Tumor Outcomes in Patients with T1 High Grade Bladder Cancer0
Differences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy0
Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra0
Single Instillation of Hypertonic Saline Immediately Following Transurethral Resection of Bladder Tumor for Recurrence Prevention –A Phase I Study0
Challenging Cases in Urothelial Cancer: Case 330
Topical Instillations of Chemotherapy for Renal Pelvic Urothelial Cancer0
The Role of Local Agents for the Treatment of Localized Upper Tract Urothelial Carcinoma: A Review of the Current Evidence0
Comparison of Health-Related Quality of Life Between Japanese and American Patients with Bladder Cancer as Measured by a Newly Developed Japanese Version of the Bladder Cancer Index0
Surface Labeling with Adhesion Protein FimH Improves Binding of Immunotherapeutic Agent Salmonella Ty21a to the Bladder Epithelium0
Evaluating Patient-Defined Priorities for Female Patients with Bladder Cancer0
Clinical Trials Corner Issue 9(1)0
Challenging Cases in Urothelial Cancer: Case 31: LG Ta Bladder Cancer0
Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx0
Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx10
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy0
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy0
Challenging Cases in Urothelial Cancer: Case 170
Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer0
Bladder Cancer Incidence and Survival in the United States and Texas Non-Latino Whites and Latinos0
25-Year Trends in Stage-Specific Incidence Rates for Bladder Cancer in a Large Statewide Registry0
Effectiveness of Prolonged Antibiotic Prophylaxis in Radical Cystectomy: Preliminary Analysis of the MACS Randomized Clinical Trial0
Switch Maintenance Therapy for Metastatic Urothelial Carcinoma0
Cost of Care in Open Cystectomy Patients Across Time and Space: Does it matter?0
Clinical Trials Corner Issue 8(2)0
PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety0
Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist’s Perspective0
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?0
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets0
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder0
New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer0
Potential of an mRNA-Based Urine Assay (Xpert® Bladder Cancer Detection1) in Hematuria Patients - Results from a Cohort Study0
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It0
BCG in Immunocompromised Patients: Is it effective? Is it safe?0
Commentary on Novitas LCD0
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer0
Clinical Trials Corner Issue 9(4)0
Challenging Cases in Urothelial Cancer: Case 320
Optimal Perioperative Chemotherapy for Muscle Invasive Bladder Cancer0
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?0
Impact of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Population Based Analysis0
Clinical Trials Corner Issue 8(4)0
The Impact of Physical Activity on Risk and Health-Related Quality of Life in Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 1810
Challenging Cases in Urothelial Cancer0
Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in Preventing COVID-19 Infection0
Antibiotics and BCG0
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”0
Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall Survival0
Clinical Trials Corner Issue 6(4)0
Adjuvant Treatment of Residual Disease Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer0
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer0
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors0
A New Standard of Care for Bladder Cancer0
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer0
Prognostic Role of mRNA-Expression of Aquaporins (AQP) 3, 4, 7 and 9 in Stage pT1 Non-Muscle-Invasive Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 220
Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model0
Challenging Cases in Urothelial Cancer: Case 250
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort0
Clinical Trials Corner Issue 7(1)0
Challenging Cases in Urothelial Cancer: Case 190
Challenging Cases in Urothelial Cancer: Case 28: Lynch Syndrome0
Iatrogenic Causes of Urothelial Cancer of the Upper Urinary Tract and Bladder0
Etiology of Treatment Delays in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer0
Festschrift in Honor of Professor Margaret Anne Knowles0
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer0
Challenging Cases in Urothelial Cancer: Case 270
What is a Bladder Cancer Molecular Subtype? – Counterpoint0
Clinical Trials Corner Issue 7(4)0
0.038290977478027